TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18240868
Drug: PEG‐IFN‐α2b monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐α2b monotherapy
Study: 15110370
Drug: Fentanyl (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.7 microg/kg bolus in 2-mL balanced salt solution)
Study: 15110370
Drug: Control (2-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2-mL balanced salt solution without analgesic)
Study: 9093341
Drug: Flow triggering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow triggering (1 and 5 l/min) during pressure support ventilation (PSV) and assisted controlled mode (A/C)
Study: 9093341
Drug: Flow triggering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow triggering (1 and 5 l/min) in A/C mode
Study: 10171655
Drug: Plasmapheresis for
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis for the production of platelet rich plasma (PRP), 20% of circulating plasma volume sequestered prior to heparinization, reinfused 10 minutes after heparin reversal.
Study: 3759280
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day atenolol
Study: 3759280
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day mepindolol
Study: 21849282
Drug: Inactivated 2009
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated 2009 H1N1 influenza vaccine (25 μg)
Study: 21849282
Drug: Inactivated 2009
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated 2009 H1N1 influenza vaccine (49 μg)
Study: 11321866
Drug: Doxazosin included
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin included in 'tight control' combination therapy
Study: 24829298
Drug: Standard PN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PN solution without taurine (control PN)
Study: 22741449
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg once daily
Study: 19256268
Drug: Factors related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors related to surgery and pharmacological treatment
Study: 15625257
Drug: Diclectin (DCL)
Normalized name: PYRITHIONE ZINC 4.63 g in 236 mL TOPICAL LOTION/SHAMPOO [DCL Zoma]
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diclectin (DCL) administered orally (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) the night before surgery, the morning of surgery, and upon hospital discharge.
Study: 14658924
Drug: Ritalin LA
Normalized name: Ritalin LA
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritalin LA (10-40 mg/day)
Study: 8867198
Drug: Full cognitive‐behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full cognitive‐behavioural treatment programme (CBT)
Study: 6234282
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg 12 hourly)
Study: 6234282
Drug: Nalidixic acid/citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalidixic acid/citrate (1 sachet 8 hourly)
Study: 31340804
Drug: CBT‐i-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐i-based group treatment (10 weekly 90-min group sessions and scheduled telephone support)
Study: 29414142
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) - one standardized Behavioral Health Consultation visit followed by three ACT-based group visits and one group booster visit.
Study: 29414142
Drug: Enhanced Treatment
Normalized name: Thera-M Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment as Usual (E-TAU) - educational pain management handouts based on standard cognitive behavioral treatment of pain.
Study: 22170358
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid (400 μg) + vitamin B-12 (100 μg) supplementation
Study: 17944890
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle (PFM) and fitness exercises, 60 minutes per session, twice a week for 3 months
Study: 11992180
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus betamethasone dipropionate 0.05% cream (mid-high-potency steroid)
Study: 11992180
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus mometasone furoate 0.1% ointment (high-potency steroid)
Study: 11992180
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus diflorasone diacetate 0.05% ointment (high-potency steroid)
Study: 11992180
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel alone
Study: 9646148
Drug: Daily prayer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily prayer or Bible study
Study: 8005121
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg plus Amiloride 2.5 mg (H+Am)
Study: 8005121
Drug: Nifedipine slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine slow release 20 mg (N)
Study: 8005121
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (At)
Study: 8005121
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg plus Chlorthalidone 6.25 mg (At+C)
Study: 2511239
Drug: TRH iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH iv administration
Study: 1094965
Drug: Feprazone 600
Normalized name: feprazone
DrugBank: Feprazone (DB13364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feprazone 600 mg daily
Study: 1094965
Drug: Aspirin 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 3.6 g daily
Study: 23333201
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 30 mg/kg (Group I)
Study: 23333201
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 40 mg/kg (Group II)
Study: 23333201
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg/kg (Group III)
Study: 23333201
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg (Group IV)
Study: 27358385
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg)
Study: 16551910
Drug: Dolasetron (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (12.5 mg) in carriers of the duplication of the CYP2D6 allele
Study: 8883233
Drug: FEC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC chemotherapy (cyclophosphamide, epirubicin, 5-fluorouracil)
Study: 2691129
Drug: Perindopril with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril with diuretic
Study: 1395119
Drug: Captopril with
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril with diuretic
Study: 1395119
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with perindopril
Study: 3903063
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy and supradiaphragmatic radiotherapy (40 Gy) for clinical stages IA and II2A
Study: 3903063
Drug: MOPP or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP or CVPP chemotherapy followed by laparotomy and radiotherapy for clinical stages II3+A and IIB
Study: 3301699
Drug: Oral polybacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polybacterial vaccine containing 1.5 X 10(9) killed Haemophilus influenzae per tablet
Study: 3301699
Drug: Three-monthly courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly courses of oral polybacterial vaccine
Study: 3301699
Drug: Increased immunizing
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased immunizing dose (60 fold) without non H. influenzae bacterial species
Study: 29138181
Drug: GIKI2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIKI2 group (GIK with intensive insulin therapy for 24 hours)
Study: 29138181
Drug: GIK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK group (GIK with nonintensive insulin therapy)
Study: 29138181
Drug: GIKI2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIKI2 group (GIK with intensive insulin therapy)
Study: 24066604
Drug: Guizhi Fuling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guizhi Fuling capsule high dose
Study: 24066604
Drug: Guizhi Fuling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guizhi Fuling capsule low dose
Study: 21397805
Drug: Topical proparacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical proparacaine anesthetic 0.5%
Study: 16567814
Drug: Fiber-enriched bread
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-enriched bread (31.2 g insoluble fiber/day)
Study: 11029326
Drug: Surfactant (Survanta,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (Survanta, 100 mg/kg)
Study: 1443354
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of cefotaxime (Schedule A)
Study: 1443354
Drug: One preoperative
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One preoperative dose followed by two postoperative doses of cefotaxime (Schedule B)
Study: 3914879
Drug: Intravenous pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pindolol for 24 hours and orally for 48 hours
Study: 27189973
Drug: BMS-932481 (γ-secretase
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-932481 (γ-secretase modulator)
Study: 18669425
Drug: Cellulose sulfate
Normalized name: CELLULOSE SULFATE
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose sulfate gel
Study: 16087822
Drug: Risedronate sodium
Normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate sodium 2.5 mg daily
Study: 2614521
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine cream mixed with 500 mg acid mantle cream
Study: 2614521
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acid mantle cream
Study: 641913
Drug: Combined azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined azathioprine and prednisone therapy
Study: 26848888
Drug: Multicomponent fitness
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent fitness training (1 hour, twice per week for 1 year)
Study: 20435263
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (angioplasty)
Study: 17997890
Drug: CIK cells
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cells treatment
Study: 17997890
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment (VitB4, batilol, leucogen, inosine, stanozolol)
Study: 15844075
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (PnCV)
Study: 2905287
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg prostaglandin E2 in gel
Study: 2905287
Drug: gel only
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel only as placebo
Study: 29037226
Drug: Xingnaojing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing injection (XNJ) combined with standard care
Study: 26226139
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (4 g/d)
Study: 18427229
Drug: Active physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active physical therapy (n=51)
Study: 18427229
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (n=57)
Study: 18427229
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (n=59)
Study: 11304723
Drug: Cefadroxila 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxila 500 mg capsule
Study: 11304723
Drug: Cefamox 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamox 500 mg capsule
Study: 9207344
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (VAQTA)
Study: 3415398
Drug: Duxil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duxil (30 mg almitrine and 10 mg raubasine, 1 tablet b.i.d.)
Study: 3415398
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet b.i.d.)
Study: 25238492
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg/day p.o
Study: 25238492
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg p.o when required
Study: 22160300
Drug: Supplemental melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental melatonin (1 or 3 mg dosages)
Study: 22245769
Drug: Tetrahydrobiopterin (BH(4))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrahydrobiopterin (BH(4)) administration
Study: 12152004
Drug: Rofecoxib, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 25 mg daily
Study: 12152004
Drug: Celecoxib, 200
Normalized name: Celecoxib, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib, 200 mg twice daily
Study: 7912878
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg manidipine
Study: 7912878
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg manidipine
Study: 31504336
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (quarterly single-dose praziquantel, triple-dose albendazole)
Study: 30325449
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of intravenous hydrocortisone followed by 0.5 mg of intravenous dexamethasone every 6 h for 4 doses (STER)
Study: 30325449
Drug: Surgery without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery without steroids (NOSTER)
Study: 28832978
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg intravenously every 2 weeks
Study: 28832978
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg intravenously every 2 weeks plus TRC105 10 mg/kg intravenously every 2 weeks
Study: 28832978
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum TGFβ levels below the median (<10.6 ng/mL)
Study: 25183694
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm (received written and oral explanations on cardiac rehabilitation benefits and eligibility, and a follow-up telephone call 2 weeks after hospital discharge)
Study: 9170825
Drug: Misoprostol vaginal
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol vaginal tablets
Study: 18282319
Drug: CATIE (Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness)
Study: 16810760
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment (n = 42)
Study: 1337607
Drug: Baclofen 15
Normalized name: baclofen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 15 mg
Study: 1337607
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg IV bolus plus 10 mg infused over 2 hr)
Study: 1337607
Drug: Baclofen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (15 mg)
Study: 2863541
Drug: Non-warfarin (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-warfarin (control)
Study: 10490723
Drug: G‐CSF started
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF started on day 0 (day 0 group)
Study: 10490723
Drug: G‐CSF started
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF started on day 5 (day 5 group)
Study: 1748141
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 (bolus injection of 3250 anti‐Xa units)
Study: 1748141
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg once daily for 8 days)
Study: 1748141
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 and Digoxin combination
Study: 6803946
Drug: Repeat oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat oral cholecystography
Study: 28720139
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intramuscular/intra-articular prednisolone, methotrexate (MTX), and golimumab (GOL) for 24 weeks
Study: 28720139
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intramuscular/intra-articular prednisolone, methotrexate (MTX), and placebo for 24 weeks
Study: 26829760
Drug: Manual Lymphatic
Normalized name: PINPOINT Lymphatics Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Lymphatic Drainage (MLD) treatments (5 sessions)
Study: 21371166
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg·kg(‐1))
Study: 21371166
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg·kg(‐1))
Study: 17874530
Drug: Low-dose fixed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fixed combination of perindopril and indapamide
Study: 17874530
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for blood glucose control
Study: 14687174
Drug: Low-dose octreotide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose octreotide
Study: 3632149
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring program for digoxin
Study: 3632149
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of therapeutic drug monitoring program
Study: 26644536
Drug: Cetuximab (CTX)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab (CTX) 400 mg/m2 as loading dose followed by 250 mg/m2 once per week with radiotherapy (RT)
Study: 26644536
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 40 mg/m2 once per week with radiotherapy (RT)
Study: 23250170
Drug: UniFil bond
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: UniFil bond with repriming treatment (UF-V and UF-VI)
Study: 17661864
Drug: Dextromethorphan (DEX)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DEX) 30 mg tablets, administered preoperatively and three times in the first 24 hours post-surgery.
Study: 17661864
Drug: Placebo (P),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P), administered following the same schedule as DEX.
Study: 9989683
Drug: High-oleate meal
Normalized name: oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-oleate meal (50 g)
Study: 9989683
Drug: High-palmitate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-palmitate meal (50 g)
Study: 9989683
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (15 g high-oleate oil)
Study: 7582157
Drug: Local Intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Intranasal Immunotherapy (LII) with macronized powder Parietaria officinalis pollen in increasing doses
Study: 367655
Drug: Imipramine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (10-20 mg)
Study: 367655
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide (10-20 mg)
Study: 27324724
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea tablet + standard treatment
Study: 25262677
Drug: Water jet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water jet device containing chlorhexidine gel (Silonite®) for home use twice daily
Study: 25262677
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with recommended oral hygiene measures without water jet usage